Immunome, Inc.
IMNM
$8.49
$0.030.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 48.11% | -70.38% | -30.39% | 72.10% | -39.79% |
| Total Depreciation and Amortization | 22.02% | 4.20% | -15.16% | 155.89% | 2.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -84.88% | 219.07% | 10.21% | -91.91% | 37.10% |
| Change in Net Operating Assets | -421.97% | 136.39% | -21.92% | -36.11% | 156.59% |
| Cash from Operations | -26.14% | -23.10% | -46.03% | -109.46% | 36.02% |
| Capital Expenditure | -166.55% | 97.11% | -1,931.78% | -8.32% | -520.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -21.37% | -84.48% | 162.69% | -226.26% | 9.92% |
| Cash from Investing | -47.85% | -59.51% | 129.50% | -119.41% | -24.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 743.12% | 3,924.56% | -56.23% | -99.50% | 62,864.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,521.25% | -96.08% | 56.50% | 96.69% | -125.68% |
| Cash from Financing | 707.71% | 6,485.25% | -56.05% | -99.68% | 295.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,035.27% | -25.12% | 90.65% | -161.03% | 2,027.94% |